Dong-A Socio Holdings wins top MSCI rating

Dong-A Socio Holdings received an AA rating, a prime rating among domestic pharmaceutical companies, in an ESG evaluation by international ratings agency MSCI.

Dong-A Socio Holdings receives a AA rating in its MSCI ESG evaluation, the highest grade for a Korean pharmaceutical company. [DONG-A SOCIO HOLDINGS]

Dong-A Socio Holdings received an AA rating, a prime rating among domestic pharmaceutical companies, in an ESG evaluation by international ratings agency MSCI.

The company’s rating has continued to improve over the years; it received a B rating in 2021 and an A rating in 2022, followed by this year’s AA rating.

According to the MSCI report, Dong-A Socio Holdings earned top marks for its human resources system, which includes setting up an anonymous source system, its anti-corruption system, ISO37001, and support for employee training.

The holding company of Dong-A Socio Group, Dong-A Holdings’ affiliates include Dong-A ST, which focuses on specialty pharmaceuticals; Dong-A Pharmaceutical, which specializes in non-prescription medicines; STgen Bio, which manufactures biopharmaceuticals, and ST Pharm, which supplies pharmaceutical ingredients.

“Our continuous efforts in socially responsible management has won recognition, as evidenced by our high ESG rating from a global evaluation agency,” an official from Dong-A Socio Holdings said. “Dong-A Socio Group will continue to expand our influence as a leading socially responsible management company.”

Meanwhile, Dong-A Socio Holdings has included social responsibility management as a category in its operating performance appraisal since 2023. This also helped the company score an A rating in its ESG evaluation from Korea Institute of Corporate Governance and Sustainability in 2022.

BY PARK YE-EUN [park.yeeun@joongang.co.kr]